IceCure Medical (ICCM) COO discloses share, option and RSU stakes

Rhea-AI Filing Summary

IceCure Medical Ltd. Chief Operating Officer Levav Shay filed an initial ownership report showing direct holdings of 144,615 ordinary shares plus several option grants. These options cover 50,000 shares at an exercise price of $1.56, 385 shares at $5.78, 80,668 shares at $3.64, 4,084 shares at $2.84, 40,705 shares at $1.51, and 98,182 shares at $0.92, with expirations ranging from 2030 to 2034. Footnotes state that some grants are already fully vested, while others vest in quarterly installments. In addition, Shay has unvested restricted share units of 81,818, 43,416 and 19,381 units from awards dated July 2, 2024, November 5, 2025 and March 16, 2026, respectively, all unvested as of March 18, 2026.

Insider Trade Summary

7 transactions reported

Mixed 7 txns

Insider Levav Shay

Role Chief Operating Officer

Type	Security	Shares	Price	Value
holding	Share option (right to buy)	--	--	--
holding	Share option (right to buy)	--	--	--
holding	Share option (right to buy)	--	--	--
holding	Share option (right to buy)	--	--	--
holding	Share option (right to buy)	--	--	--
holding	Share option (right to buy)	--	--	--
holding	Ordinary shares	--	--	--

Holdings After Transaction: Share option (right to buy) — 50,000 shares (Direct); Ordinary shares — 144,615 shares (Direct)

Footnotes (1)

1. Represents (i) 81,818 restricted share units ("RSUs") granted on July 2, 2024, 25% of which vest on July 29, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, (ii) 43,416 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026, and the remaining 75% vesting in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, and (iii) 19,381 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026. The options were granted on September 6, 2020, 25% of which vested on September 6, 2021, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 50,000 options are fully vested. The options were granted with an exercise price of NIS 4.84 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.56 per share. The options were granted on April 28, 2021, 25% of which vested on April 28, 2022, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 385 options are fully vested. The options were granted with an exercise price of NIS 17.92 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $5.78 per share. The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 80,668 options are fully vested. The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share. The options were granted on March 23, 2022, 25% of which vested on March 23, 2023, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 3,828 options are vested. The options were granted with an exercise price of NIS 8.81 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.84 per share. The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 30,528 options are vested. The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share. The options were granted on July 2, 2024, 25% of which vested on July 2, 2025, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 36,818 options are vested.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Levav Shay

(Last) (First) (Middle)

7 HA'ESHEL ST., PO BOX 3163

(Street)

CAESAREA 3079504

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
IceCure Medical Ltd. [ ICCM ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares	144,615(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share option (right to buy)	(2)	09/06/2030	Ordinary shares	50,000	$1.56(3)	D
Share option (right to buy)	(4)	04/28/2031	Ordinary shares	385	$5.78(5)	D
Share option (right to buy)	(6)	01/12/2032	Ordinary shares	80,668	$3.64(7)	D
Share option (right to buy)	(8)	03/23/2032	Ordinary shares	4,084	$2.84(9)	D
Share option (right to buy)	(10)	02/19/2033	Ordinary shares	40,705	$1.51(11)	D
Share option (right to buy)	(12)	07/02/2034	Ordinary shares	98,182	$0.92	D

Explanation of Responses:

1. Represents (i) 81,818 restricted share units ("RSUs") granted on July 2, 2024, 25% of which vest on July 29, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, (ii) 43,416 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026, and the remaining 75% vesting in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, and (iii) 19,381 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026.

2. The options were granted on September 6, 2020, 25% of which vested on September 6, 2021, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 50,000 options are fully vested.

3. The options were granted with an exercise price of NIS 4.84 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.56 per share.

4. The options were granted on April 28, 2021, 25% of which vested on April 28, 2022, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 385 options are fully vested.

5. The options were granted with an exercise price of NIS 17.92 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $5.78 per share.

6. The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 80,668 options are fully vested.

7. The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share.

8. The options were granted on March 23, 2022, 25% of which vested on March 23, 2023, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 3,828 options are vested.

9. The options were granted with an exercise price of NIS 8.81 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.84 per share.

10. The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 30,528 options are vested.

11. The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share.

12. The options were granted on July 2, 2024, 25% of which vested on July 2, 2025, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 36,818 options are vested.

	/s/ shay Levav	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Levav Shay’s Form 3 filing for IceCure Medical (ICCM) show?

The Form 3 shows COO Levav Shay’s initial ownership in IceCure Medical, including 144,615 ordinary shares, multiple option grants with exercise prices between $0.92 and $5.78, and several unvested RSU awards with detailed vesting schedules.

How many IceCure Medical (ICCM) ordinary shares does Levav Shay hold?

Levav Shay directly holds 144,615 ordinary shares of IceCure Medical. This figure represents his reported direct equity stake in the company’s common equity, separate from any options or restricted share units disclosed in the same filing.

What stock options are reported for Levav Shay in IceCure Medical (ICCM)?

The filing lists options over 50,000 shares at $1.56, 385 at $5.78, 80,668 at $3.64, 4,084 at $2.84, 40,705 at $1.51, and 98,182 at $0.92, with expirations between 2030 and 2034.

Are Levav Shay’s IceCure Medical (ICCM) options vested according to the filing?

Footnotes state that certain grants, including 50,000, 385 and 80,668 options, are fully vested as of March 18, 2026. Other grants vest 25% on the first anniversary date, with the remaining 75% vesting in equal quarterly 6.25% installments.

What restricted share units (RSUs) does Levav Shay hold in IceCure Medical (ICCM)?

The footnotes describe RSU grants of 81,818, 43,416 and 19,381 units, dated July 2, 2024, November 5, 2025 and March 16, 2026. Each award vests 25% on its first anniversary, with the remaining 75% vesting in 6.25% quarterly installments, all unvested as of March 18, 2026.

Does Levav Shay’s Form 3 show any recent IceCure Medical (ICCM) share purchases or sales?

The report functions as an initial ownership statement and only lists existing holdings in ordinary shares, options and RSUs. The transaction summary shows no categorized buys, sells, exercises, gifts or tax withholdings, only holding entries with unknown transaction codes.